We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Novaccess Global Inc (XSNX) USD0.01

Sell:$0.008 Buy:$0.008 Change: $0.00271 (51.23%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.008
Buy:$0.008
Change: $0.00271 (51.23%)
Deal now Deal for just £11.95 per trade in a Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.008
Buy:$0.008
Change: $0.00271 (51.23%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.

Contact details

Address:
8584 E. WASHINGTON STREET, NO. 127
CHAGRIN FALLS
44023
United States
Telephone:
+1 (213) 6429268
Website:
https://novaccessglobal.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
XSNX
ISIN:
US67001N1072
Market cap:
$166,040
Shares in issue:
27.67 million
Sector:
Biotechnology
Exchange:
Off Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Dwain Moris - Irvin
    Chief Executive Officer, Director
  • Neil Laird
    Fractional Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.